MAP2K7 and adenocarcinoma: Matched trial therapies were available for 20% (3/15) of patients with adenocarcinoma (NOS), 13% (2/15) to AKT1 inhibitors (NCT01226316, NCT02338622) and 7% (1/15) to RAF/MEK inhibitors, based on a KRAS mutation through NCT02407509.